Vericel 경영진
경영진 기준 점검 3/4
Vericel CEO는 Nick Colangelo, Mar2013 에 임명되었습니다 의 임기는 13.42 년입니다. 총 연간 보상은 $11.16M, 7.7% 급여 및 92.3% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $13.94M 가치에 해당하는 회사 주식의 0.61% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 4.9 년과 13.4 년입니다.
핵심 정보
Nick Colangelo
최고경영자
US$11.2m
총 보수
| CEO 급여 비율 | 7.71% |
| CEO 재임 기간 | 13.4yrs |
| CEO 지분 보유율 | 0.6% |
| 경영진 평균 재임 기간 | 4.9yrs |
| 이사회 평균 재임 기간 | 13.4yrs |
최근 경영진 업데이트
Recent updates
내러티브 업데이트 • Jul 31
VCEL: Raised Guidance And Buyback Will Support Stronger Forward Repricing
Analysts have raised their fair value estimate for Vericel stock from $42.00 to $55.00, citing recent price target increases that follow reported MACI performance in Q2, as well as guidance they consider achievable for the second half of the year. Analyst Commentary Recent Street research on Vericel has focused on how current expectations for MACI and the broader MedTech backdrop feed into risk and reward for the stock.
내러티브 업데이트 • Jul 17
VCEL: Raised Outlook And New Headquarters Will Support Stronger Future Position
Vericel's implied fair value estimate has moved from about $53.88 to $57.14 as analysts adjust their price targets, citing updated expectations around revenue growth, profit margins and sector volatility. What’s in the News for Vericel Vericel approved an amendment to the company’s bylaws to reflect the relocation of its principal executive offices to a new global headquarters at 25 Blue Sky Drive, Burlington, Massachusetts 01803.
내러티브 업데이트 • Jun 26
VCEL: Strong Q1 Execution And BARDA Contract Will Drive Future Upside
Analysts have raised their fair value estimate for Vericel to $70.00 from $64.00, citing updated assumptions on revenue growth, profit margins, and future P/E, even as some Street targets such as Truist's have recently moved lower. What’s in the News for Vericel Analysts highlighted Vericel’s recent first quarter results, where revenues were reported at 7.6% above expectations and statutory losses were reduced, according to a summary of Wall Street research (source: Zacks / TD Cowen coverage summary).분석 기사 • Jun 22
Vericel (VCEL) Stock Could Be 37.3% Undervalued After Earnings Beat And Fund Buying
Vericel (VCEL) has drawn fresh attention after institutional holders such as BlackRock and State Street lifted their positions, and the company reported quarterly earnings per share that came in above market expectations. See our latest analysis for Vericel. Vericel's share price has picked up momentum recently, with a 1-day share price return of 2.48%, 7-day return of 7.05%, and 90-day return of 23.57%. This comes even though the 1-year total shareholder return declined 4.57% and the 5-year...분석 기사 • May 09
The Vericel Corporation (NASDAQ:VCEL) First-Quarter Results Are Out And Analysts Have Published New Forecasts
As you might know, Vericel Corporation ( NASDAQ:VCEL ) just kicked off its latest quarterly results with some very...새로운 내러티브 • May 02
Expanded Cell Therapy Capacity And Burn Care Franchise Will Drive Multiyear Upside Potential
Catalysts About Vericel Vericel develops and manufactures advanced cell therapies for cartilage repair and severe burn care. What are the underlying business or industry changes driving this perspective?새로운 내러티브 • Apr 17
Expanded Cell Therapy Pipeline Will Face Execution Risks Yet Ultimately Support Healthier Business
Catalysts About Vericel Vericel develops and manufactures advanced cell therapies for sports medicine and burn care, including MACI for cartilage repair and Epicel and NexoBrid in burn care. What are the underlying business or industry changes driving this perspective?Seeking Alpha • Jan 04
Vericel: Growth Plans May Have Run Out Of Gas (Rating Downgrade)
Summary Vericel (VCEL) is rated a hold due to inconsistent growth, fluctuating profitability, and limited near-term upside at current valuation. VCEL’s future hinges on scaling MACI, as Epicel and Nexobrid have stalled and face capped demand in niche markets. International expansion and MACI Arthro could drive growth, but execution risks and delayed timelines temper confidence in acceleration. Despite strong cash and no long-term debt, persistent SG&A growth and negative free cash flow highlight challenges in achieving sustainable profitability. Read the full article on Seeking Alpha분석 기사 • Nov 12
There's No Escaping Vericel Corporation's (NASDAQ:VCEL) Muted Revenues Despite A 29% Share Price Rise
Vericel Corporation ( NASDAQ:VCEL ) shares have had a really impressive month, gaining 29% after a shaky period...분석 기사 • Jun 16
Does Vericel (NASDAQ:VCEL) Deserve A Spot On Your Watchlist?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...분석 기사 • May 01
Risks To Shareholder Returns Are Elevated At These Prices For Vericel Corporation (NASDAQ:VCEL)
With a median price-to-sales (or "P/S") ratio of close to 9.6x in the Biotechs industry in the United States, you could...Seeking Alpha • Mar 06
Vericel: Scalable Growth With Strong Margins
Summary Vericel's niche in regenerative medicine is undervalued, with FDA-approved products like MACI, Epicel, and NexoBrid driving steady revenue growth and profitability. The company's strong financials include $167 million in cash, zero debt, and a 16% year-over-year revenue increase, highlighting operational efficiency. MACI's expansion into ankle cartilage repair and a robust pipeline suggest significant future earnings potential, despite current market hesitations. VCEL's strategy focuses on indication expansion and market penetration, aiming for long-term margin growth and reduced vulnerability to high-risk drug development. Read the full article on Seeking AlphaSeeking Alpha • Dec 19
Vericel Corporation: Hard To Justify Current Valuation
Summary Vericel Corporation, specializing in cellular therapies for sports medicine and severe burn care, has seen a 40% rise in its stock recently. Core products include MACI, NexoBrid, and Epicel, with Q3 revenues rising 27% year-over-year to $57.9 million, beating expectations. The company is turning the corner on profitability, but valuations look stretched at current trading levels. An analysis around Vericel follows in the paragraphs below. Read the full article on Seeking Alpha분석 기사 • Nov 09
Vericel Corporation (NASDAQ:VCEL) Stock Rockets 32% As Investors Are Less Pessimistic Than Expected
Vericel Corporation ( NASDAQ:VCEL ) shares have had a really impressive month, gaining 32% after a shaky period...
새로운 내러티브 • Sep 10
MACI And NexoBrid Drive Record Revenues And Profit Growth, Setting Stage For Robust Future Performance
Expansion of MACI and NexoBrid markets driving record revenues, indicating significant future revenue growth.분석 기사 • Jul 12
What Vericel Corporation's (NASDAQ:VCEL) P/S Is Not Telling You
With a median price-to-sales (or "P/S") ratio of close to 11.3x in the Biotechs industry in the United States, you...분석 기사 • May 11
Vericel Corporation (NASDAQ:VCEL) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
Vericel Corporation ( NASDAQ:VCEL ) just released its first-quarter report and things are looking bullish. Revenues and...분석 기사 • Apr 26
It's Unlikely That The CEO Of Vericel Corporation (NASDAQ:VCEL) Will See A Huge Pay Rise This Year
Key Insights Vericel will host its Annual General Meeting on 1st of May Salary of US$790.0k is part of CEO Nick...분석 기사 • Mar 02
Is There An Opportunity With Vericel Corporation's (NASDAQ:VCEL) 49% Undervaluation?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Vericel fair value estimate is US$87.12 Vericel is estimated...분석 기사 • Feb 02
Revenues Not Telling The Story For Vericel Corporation (NASDAQ:VCEL) After Shares Rise 29%
Vericel Corporation ( NASDAQ:VCEL ) shareholders would be excited to see that the share price has had a great month...분석 기사 • May 05
Vericel Corporation's (NASDAQ:VCEL) Shareholders Might Be Looking For Exit
It's not a stretch to say that Vericel Corporation's ( NASDAQ:VCEL ) price-to-sales (or "P/S") ratio of 9.4x right now...CEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | US$24m |
| Mar 31 2026 | n/a | n/a | US$21m |
| Dec 31 2025 | US$11m | US$860k | US$17m |
| Sep 30 2025 | n/a | n/a | US$13m |
| Jun 30 2025 | n/a | n/a | US$7m |
| Mar 31 2025 | n/a | n/a | US$3m |
| Dec 31 2024 | US$10m | US$830k | US$10m |
| Sep 30 2024 | n/a | n/a | US$4m |
| Jun 30 2024 | n/a | n/a | US$789k |
| Mar 31 2024 | n/a | n/a | US$451k |
| Dec 31 2023 | US$7m | US$790k | -US$3m |
| Sep 30 2023 | n/a | n/a | -US$10m |
| Jun 30 2023 | n/a | n/a | -US$13m |
| Mar 31 2023 | n/a | n/a | -US$17m |
| Dec 31 2022 | US$9m | US$760k | -US$17m |
| Sep 30 2022 | n/a | n/a | -US$18m |
| Jun 30 2022 | n/a | n/a | -US$16m |
| Mar 31 2022 | n/a | n/a | -US$11m |
| Dec 31 2021 | US$13m | US$730k | -US$7m |
| Sep 30 2021 | n/a | n/a | US$214k |
| Jun 30 2021 | n/a | n/a | US$9m |
| Mar 31 2021 | n/a | n/a | US$4m |
| Dec 31 2020 | US$4m | US$675k | US$3m |
| Sep 30 2020 | n/a | n/a | US$145k |
| Jun 30 2020 | n/a | n/a | -US$3k |
| Mar 31 2020 | n/a | n/a | -US$12m |
| Dec 31 2019 | US$5m | US$634k | -US$10m |
보상 대 시장: Nick의 총 보수(USD11.16M)는 US 시장에서 비슷한 규모 기업의 평균(USD5.17M)보다 높습니다.
보상과 수익: Nick의 보상은 지난 1년 동안 회사 실적과 일치했습니다.
CEO
Nick Colangelo (62 yo)
13.4yrs
재임 기간
US$11,156,368
보수
Mr. Dominick C. Colangelo, also known as Nick, Esq., has been the Chief Executive Officer and President at Vericel Corporation since March 1, 2013 and served as its Treasurer since May 7, 2014. He has been...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| CEO, President & Director | 13.4yrs | US$11.16m | 0.61% $ 13.9m | |
| CFO & Treasurer | 5.6yrs | US$3.24m | 0.031% $ 713.0k | |
| Chief Operating Officer | 7.2yrs | US$3.62m | 0.032% $ 730.3k | |
| Chief Legal Officer | 6.8yrs | US$2.55m | 0.0032% $ 73.4k | |
| Chief Medical Officer | 8yrs | US$2.56m | 0.15% $ 3.4m | |
| Principal Accounting Officer | 4.5yrs | 데이터 없음 | 0.0021% $ 48.1k | |
| Vice President of Finance & Investor Relations | no data | 데이터 없음 | 데이터 없음 | |
| Chief Marketing Officer | 1.6yrs | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Corporate Development & Strategy | 4.9yrs | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Sales | 2.6yrs | 데이터 없음 | 데이터 없음 | |
| Chief Human Resources Officer | 2.1yrs | US$3.21m | 0.0036% $ 82.6k | |
| Senior Vice President of Operations | 4.5yrs | 데이터 없음 | 데이터 없음 |
4.9yrs
평균 재임 기간
57.5yo
평균 나이
경험이 풍부한 관리: VCEL의 경영진은 경험이 있음으로 간주됩니다(평균 재임 4.9 년).
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| CEO, President & Director | 13.4yrs | US$11.16m | 0.61% $ 13.9m | |
| Independent Director | 11.6yrs | US$357.80k | 0.036% $ 815.1k | |
| Independent Director | 11.6yrs | US$348.43k | 0.037% $ 837.5k | |
| Independent Chairman & Lead Director | 20.6yrs | US$395.30k | 0.064% $ 1.5m | |
| Independent Director | 20.9yrs | US$365.30k | 0.13% $ 2.9m | |
| Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | 16.3yrs | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | 16.3yrs | 데이터 없음 | 데이터 없음 | |
| Independent Director | 13yrs | US$355.30k | 0.068% $ 1.6m | |
| Independent Director | 5.2yrs | US$342.80k | 0.031% $ 705.9k |
13.4yrs
평균 재임 기간
65.5yo
평균 나이
경험이 풍부한 이사회: VCEL의 이사회는 노련하고 경험이 풍부합니다(평균 재임 13.4 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/08/14 02:31 |
| 종가 | 2026/08/14 00:00 |
| 수익 | 2026/06/30 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Vericel Corporation는 20명의 분석가가 다루고 있습니다. 이 중 8명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Keay Nakae | Ascendiant Capital Markets LLC |
| Michael Gorman | BTIG |
| Caitlin Cronin | Canaccord Genuity |